CBLLCBLLHealthcare · Medical Devices

CBLL Stock Forecast: Ceribell, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$27
+6.37% on the day

The 8 Wall Street analysts covering Ceribell, Inc. hold a median 12-month price target of $31 — +13.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.1B
Ticker Nerd rank
44/ 100
Median analyst target
$31
Analysts covering
8
Revenue$28.1M+32.5% y/y
Operating income−$20.0M
Net income−$19.3M
Free cash flow−$12.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
−1.0%
YTD
+24.9%
1Y
+100.8%
From 52W high
−3.1%
From 52W low
+100.8%
$14
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Ceribell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
44/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Accruals
74
Volatility
66
Value
49
Revisions
39
Quality
34
Growth
29
Issuance
24

Momentum (99): The shares have been drifting up relative to others.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CBLL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CBLL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26CBLLHigh $33Median $31Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8
Buy
0
Hold
0
Sell
$30
Low
$31
Median
$33
High

The green dot is the last close — the median target sits +13.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
4 Nov 2026Canaccord GenuityMaintainsBuy$26 → $33
2 Oct 2026TD CowenMaintainsBuy$29 → $33
11 Sept 2026BTIGReiteratesBuy$30
18 Aug 2026BTIGMaintainsBuy$28 → $30
11 Aug 2026BTIGReiteratesBuy$28
11 Aug 2026Canaccord GenuityMaintainsBuy$25 → $26
12 May 2026Canaccord GenuityMaintainsBuy$28 → $25
28 Jan 2026BTIGReiteratesBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
15 Dec 2025BTIGReiteratesBuy—
5 Nov 2025JP MorganMaintainsOverweight—
5 Nov 2025TD CowenMaintainsBuy—
21 Oct 2025Raymond JamesInitiatesStrong Buy—
4 Apr 2025Ladenburg ThalmannInitiatesBuy—
26 Feb 2025Canaccord GenuityMaintainsBuy—
9 Dec 2024Canaccord GenuityMaintainsBuy—
9 Dec 2024TD CowenMaintainsBuy—
13 Nov 2024Canaccord GenuityMaintainsBuy—
5 Nov 2024B of A SecuritiesInitiatesBuy—
5 Nov 2024Canaccord GenuityInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CBLL.

Market Radar

This page is one stock. Monday covers all of them.

CBLL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CBLL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Ceribell, Inc. returned +100.8% against +6.9% for the S&P 500, dividends included.

CBLL vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Jan 26Apr 26Jul 26Oct 26CBLLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CBLL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
9.8×

Cheaper than 12% of US stocks

Price / book
9.0×

Cheaper than 9% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
29.9%

Higher than 78% of US stocks

Earnings growth (YoY)
—
Gross margin
92.3%

Higher than 97% of US stocks

Operating margin
−69.8%

Higher than 16% of US stocks

Net margin
−68.0%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−52.5%

Higher than 21% of US stocks

Return on assets
−26.6%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ceribell, Inc. has a market value of $1.1B and an enterprise value of $967.9M.

  • Revenue in the twelve months to 30 June 2026: $102.0M. The latest quarter grew 32.5% year on year.

  • Net income over the same four quarters: −$66.0M, a −64.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.76.

  • Free cash flow in the twelve months to 30 June 2026: −$54.7M.

  • Shares outstanding: 38.2M.

  • Ceribell, Inc. employs 327 people — $312K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

CBLL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CBLLCeribell, Inc.$1.1B44
SIBNSI-BONE, Inc.$1.0B85
IRMDIRadimed Corp.$1.0B80
IARTIntegra LifeSciences Holdings Corp.$1.0B81
ATECAlphatec Holdings, Inc.$1.0B63
AHCOAdaptHealth Corp.$978.6M68
TNDMTandem Diabetes Care, Inc.$1.2B66

Take a look at CBLL’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Ceribell, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CBLL

What is the CBLL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Ceribell, Inc. have a median 12-month price target of $31, with estimates ranging from $30 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CBLL stock a buy right now?

Of the 8 analysts covering Ceribell, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ceribell, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CBLL?

As at 21 Nov 2026, Ceribell, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will CBLL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +13.2% from the last close, and Ticker Nerd's factor model ranks Ceribell, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CBLL stock forecast for 2030?

No analyst covering Ceribell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CBLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $33 over the next 12 months.

How has CBLL stock performed over the past year?

Ceribell, Inc. returned +100.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ceribell, Inc. do?

Ceribell Inc. is a medical technology company focused on acute-care neurodiagnostics. Ceribell develops the Ceribell System, a point-of-care EEG platform designed to help clinicians detect and manage serious neurological conditions at the bedside.

Company

About Ceribell, Inc.

Ceribell Inc. is a medical technology company focused on acute-care neurodiagnostics. Ceribell develops the Ceribell System, a point-of-care EEG platform designed to help clinicians detect and manage serious neurological conditions at the bedside. Its product suite includes disposable EEG headbands, a portable battery-operated recorder, cloud-based EEG software, and Clarity, an AI-powered seizure detection algorithm. These tools are used in hospitals and other urgent-care settings to support rapid brain monitoring, real-time interpretation, and faster clinical decision-making. Ceribell’s technology is aimed at making EEG more accessible, efficient, and practical for frontline healthcare teams working with suspected seizures and other critical neurological events.

CEO Dr. Xingjuan Chao Ph.D. · 327 employees · United States · https://www.ceribell.com